Key Insights

Highlights

Treatment Research

1 treatments under study, led by Imipenemrelebactam

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04785924Phase 4Withdrawn

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

Showing all 1 trials

Research Network

Common Treatments

  • Imipenemrelebactam1

Active Sponsors

  • Wake Forest University Health Sciences1
  • Merck Sharp & Dohme LLC1

Top Investigators

Related Conditions

  • Carbapenemresistant Enterobacteriaceae Infection1
  • Gramnegative Bacterial Infections1
  • Antibiotic Resistant Infection1

Activity Timeline